NDAORALTABLETPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 15h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASCOR (bepridil hydrochloride) is an oral calcium channel blocker approved in 1990 for cardiovascular indications. It reduces cardiac workload and improves coronary blood flow through calcium antagonism. The drug targets patients with angina or related ischemic heart conditions.
LOE Approaching
Declining asset nearing exclusivity loss with minimal team expansion; legacy product management focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VASCOR offers limited career growth due to approaching loss of exclusivity and minimal linked job openings. This is a legacy product best suited for professionals seeking stable, administrative-focused roles in lifecycle management rather than innovation or growth.
Brand ManagerRegulatory Affairs Specialist
Worked on VASCOR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.